The Retina Society

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Jesse L. Berry, MD, discusses prospective data on aqueous humor liquid biopsy in retinoblastoma and explains how molecular markers from the aqueous are beginning to guide recurrence risk, treatment intensity, and the workup of otherwise diagnostically inaccessible intraocular lesions.

At Retina Society 2026, Eileen Hwang, MD, PhD, discusses a meta-analysis finding a 1.78 times higher retinal detachment rate in COL2A1 vs COL11A1 Stickler syndrome and the case for prophylactic laser.

At Retina Society 2026, Nimesh Patel, MD, discusses how stage 2 ROP before 34 weeks raises the treatment rate and why he urges early referral and a risk-tailored approach to care.

Charles Wykoff, MD, PhD, reviews LUGANO safety and treatment burden data, including a 42% injection reduction with vorolanib insert vs aflibercept, despite a missed primary end point.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

Mark P. Breazzano, MD, FACS, shares findings from a TriNetX real-world database analysis on how HIV co-infection influences RPR titers in patients with ocular syphilis.

Chhablani reports revakinagene taroretcel-lwey slowed cavitation volume growth and preserved photoreceptor structure in MacTel type 2.

Dilsher S. Dhoot, MD, FASRS, breaks down the Phase 3 SOL-1 results on intravitreal axitinib hydrogel (OTX-TKI) and aflibercept on vision maintenance.

Talisa Forest (de Carlo), MD, discusses how dynamic complement biomarkers track with artificial intelligence-measured geographic atrophy progression.

K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

Christine Kay, MD, discusses 4-year REMAIN data showing durable visual acuity gains with MCO-010, a mutation-agnostic intravitreal optogenetic therapy for advanced retinitis pigmentosa.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

Emami-Naeini previews Retina Society 2026's shift toward AI-derived, quantitative biomarkers in imaging and therapeutics.

Christine Kay, MD, presents new findings on MCO-010, a novel optogenetic therapy improving vision in retinitis pigmentosa patients at the Retina Society meeting.

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

Sumit Sharma, MD, sat down with Sydney Crago of Modern Retina to discuss his presentation on the 3 tyrosine kinase inhibitors currently in development for the treatment of retina conditions at the Retina Society meeting being held this year in Lisbon, Portugal.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for Aflibercept 8 mg and 2 mg.

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular degeneration at the Retina Society 57th Annual Scientific Meeting in Lisbon, Portugal.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 clinical trial results for ONL-1204 for rhegmatogenous retinal detachment from the Retina Society meeting being held this year in Lisbon, Portugal.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the 12-month outcomes of the FARETINA and FARWIDE studies from the Retina Society meeting being held this year in Lisbon, Portugal.

CHG is an effective alternative antiseptic to PI and the cost is outweighed by increased patient comfort.

In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) demonstrated 80% tumor control rate, 90% visual acuity preservation, and a favorable safety profile.

Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.

Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly Diagnosed Geographic Atrophy: An Observational, Retrospective US-based Cohort Study at the annual Retina Society meeting being held this year in Lisbon, Portugal

The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.

Mathew MacCumber, MD, PhD, FASRS, spoke with Modern Retina about his presentation at the recent Retina Society meeting in New York City titled, "0.19 mg Fluocinolone Acetonide (FAc) Implant Improves Vision and Treatment Burden in Patients with Diabetic Macular Edema: The PALADIN Study."

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.